ST Huluwa announced that the company plans to restructure the use of internal funds for “drug research and development projects” based on factors such as the industry environment. The R&D project for levosalbutamol hydrochloride, ipratropium bromide atomized inhalation solution and afoterol tartrate atomized inhalation solution was terminated. The former is to be transferred 17.6 million yuan to Beijing Yingkerui Innovative Pharmaceutical Research Co., Ltd. The capital raised involved a change of investment direction of 1.04 million yuan, accounting for 5.30% of the total amount raised. The matter has been reviewed by the board of directors and still needs to be reviewed by the shareholders' meeting.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.